Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions
- PMID: 20978876
- DOI: 10.1007/s12185-010-0711-9
Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions
Similar articles
-
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.Haematologica. 2003 Dec;88(12):ECR37. Haematologica. 2003. PMID: 14688010 No abstract available.
-
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.Clin Cancer Res. 2001 Jun;7(6):1490-6. Clin Cancer Res. 2001. PMID: 11410481
-
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527. Expert Opin Biol Ther. 2008. PMID: 18352855 Review.
-
Gemtuzumab ozogamicin: time to resurrect?J Clin Oncol. 2012 Nov 10;30(32):3921-3. doi: 10.1200/JCO.2012.43.0132. Epub 2012 Sep 17. J Clin Oncol. 2012. PMID: 22987091 Free PMC article. No abstract available.
-
What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?Curr Hematol Malig Rep. 2007 May;2(2):104-10. doi: 10.1007/s11899-007-0015-1. Curr Hematol Malig Rep. 2007. PMID: 20425358 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical